Devers Shannon L.

Devers Shannon L., Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals (IONS), has been a consistent seller of company stock over the past three months, with no open-market purchases recorded during that period. Across 39 total Form 4 filings, all involving IONS, the insider has disposed of shares worth approximately $8.99 million while acquiring no shares through open-market buys. The recent activity is heavily weighted toward sales, with 11 sell transactions logged since early January 2026, alongside several option exercises and compensatory awards that typically precede such dispositions. The pattern is most pronounced in the first week of January 2026, when Devers executed a cluster of sales on January 7 totaling roughly $3.76 million, including a single transaction valued at $2.18 million. These sales were paired with option exercises of similar magnitude—such as a $1.45 million exercise on the same date—suggesting a routine conversion of vested equity into cash. A subsequent sale on January 16 brought in $634,410, followed by a $323,490 sale on January 22. The selling continued into March, with three sales on March 3 alone, including one for $1.13 million, and a final disposition on April 2 worth $458,613. Notably, Devers has not initiated any open-market purchases (code "P") in the recent window, and the only non-sale transactions are compensatory grants (code "A") valued at zero and mechanical option exercises (code "M"). This one-directional flow—exercising options and immediately selling the underlying shares—is typical of an executive monetizing equity compensation rather than expressing a bullish or bearish view. The absence of any buy-side activity, combined with the steady cadence of sales across multiple months, underscores a clear disposition bias in Devers’s recent trading behavior.